Launch of Retail Offer

Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces a retail offer via BookBuild (the "Retail Offer") of new Ordinary Shares ("Ordinary Shares") of 0.025 pence each in the capital of the Company (the "Retail Offer Shares") to raise up to £200,000 at an issue price of 6 pence per Retail Offer Share (the "Placing Price").

In addition to the Retail Offer, the Company also conducted a placing of new ordinary shares (the "Placing Shares" and together with the Retail Offer Shares, the ("Fundraising Shares") at the Placing Price (the "Placing" and together with the Retail Offer, the "Fundraising"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing and completion of the Placing is not conditional on the completion of the Retail Offer. Full details of the Fundraising, including the background to and reasons for the Placing and Retail Offer is included in the separate announcement released by the Company at 5:04 p.m. on 13 October 2025.

The Placing Price represents a discount of approximately 0.8% per cent to the closing share price of 6.05 pence per existing Ordinary Share on 10 October 2025.

Completion of the Retail Offer is conditional, inter alia, upon the Placing proceeding, Admission and Resolutions being duly passed by Shareholders at the General Meeting to be held at 9.00 a.m. on 30 October 2025 at the offices of the Company at York Biotech Campus, Sand Hutton, York, England, YO41 1LZ and Admission. Subject to these conditions being satisfied, Admission of the Retail Offer Shares is expected to take place at 8:00 a.m. on 31 October 2025.

For the avoidance of doubt, the Retail Offer is not part of the Placing and is the sole responsibility of the Company. The Bookrunner does not have any responsibilities, obligations, duties or liabilities (whether arising pursuant to any contract, law, regulation, or tort) in relation to the same.

Expected Timetable in relation to the Retail Offer

Retail Offer

The Company values its retail shareholder base, which has supported the Company alongside institutional investors. Given the support of retail shareholders, the Company believes that it is appropriate to provide its eligible retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website:

The Retail Offer will be open to eligible investors in the United Kingdom at 8:30am on 14 October 2025. The Retail Offer is expected to close at 4:30pm on 16 October 2025. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed.

If any intermediary has any questions about how to participate in the Retail Offer on behalf of existing retail shareholders, please contact the Retail Offer Coordinator at Zeus Capital Limited or BookBuild at email: support@bookbuild.live.

There is a minimum subscription of £100.00 per investor under the terms of the Retail Offer which is open to investors in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/47DY97/authorised-intermediaries

Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released at 5:04 p.m. on 13 October 2025 in respect of the Proposed Placing to raise up to £3.34 million (before expenses) and Retail Offer to raise up to £200,000 (before expenses) unless the context provides otherwise.

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:

"We value the support the Company receives from its retail investors, and are pleased to offer participation in this Retail Offer to existing shareholders on the same terms as the Placing with institutional investors. This subscription, alongside the Placing, will allow us to accelerate the expansion of our lateral flow manufacturing capacity in USA and provide additional working capital for the execution of the larger full-service CDMO contracts the Company is winning. I would like to thank shareholders for their continued support."

UK Product Governance Requirements

EU Product Governance Requirements